Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Starch-binding domain-containing protein 1 (STBD1) is a membrane-associated protein that contains a C-terminal carbohydrate-binding module (CBM20) and an N-terminal hydrophobic region, the latter likely targeting it to the endoplasmic reticulum and/or lysosomal membranes[1][2][3]. STBD1 is predominantly expressed in liver, muscle, and heart, which are key tissues for glycogen storage[3]. Its main biological function is as a cargo receptor mediating glycophagy, the selective autophagic degradation of glycogen, by binding glycogen and interacting with autophagy machinery such as members of the ATG8 protein family (e.g., GABARAPL1)[2][4]. STBD1 binds glycogen through its CBM20 domain and anchors it to intracellular membranes, facilitating its delivery to lysosomes. It may be especially important in the disposal of abnormally structured glycogen, implicating it in the pathogenesis or prevention of several glycogen storage diseases[4]. Current evidence does not support a role for STBD1 as a direct therapeutic target, and there are no drugs or established biomarkers associated with this protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Starch-binding domain-containing protein 1 (STBD1).